牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced positive top-line results from its Phase I clinical trial for MTX110 in treating diffuse midline glioma (DMG). The trial, conducted by Columbia University Irving Medical Center, showed a median overall survival of 16.5 months compared to 10.0 months in a comparable cohort. Despite not being powered for efficacy, the results were favorable and will be presented at the International Symposium on Pediatric Neuro-Oncology in July 2024. The study also reported a severe adverse event in one patient, deemed unrelated to the study drug. Additionally, Biodexa provided an update on tolimidone, a potential treatment for Type 1 diabetes. An in vitro experiment conducted by a CRO did not yield conclusive results, but the company plans to proceed with an in vivo preclinical study and a Phase IIa study later in the year. Biodexa's R&D update was included in their Form 6-K filing with the SEC for February 2024, and the press release was dated February 23, 2024.
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced positive top-line results from its Phase I clinical trial for MTX110 in treating diffuse midline glioma (DMG). The trial, conducted by Columbia University Irving Medical Center, showed a median overall survival of 16.5 months compared to 10.0 months in a comparable cohort. Despite not being powered for efficacy, the results were favorable and will be presented at the International Symposium on Pediatric Neuro-Oncology in July 2024. The study also reported a severe adverse event in one patient, deemed unrelated to the study drug. Additionally, Biodexa provided an update on tolimidone, a potential treatment for Type 1 diabetes. An in vitro experiment conducted by a CRO did not yield conclusive results, but the company plans to proceed with an in vivo preclinical study and a Phase IIa study later in the year. Biodexa's R&D update was included in their Form 6-K filing with the SEC for February 2024, and the press release was dated February 23, 2024.
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC宣佈了其用於治療瀰漫性中線神經膠質瘤（DMG）的 MTX110 I 期臨床試驗的業績良好。該試驗由哥倫比亞大學歐文醫學中心進行，顯示中位總存活率爲16.5個月，而同類隊列的中位總存活率爲10.0個月。儘管療效不佳，但結果還是不錯的，將在2024年7月的兒科神經腫瘤學國際研討會上發表。該研究還報告了一名患者的嚴重不良事件，被認爲與研究藥物無關。此外，Biodexa提供了託利米酮的最新情況，託利米酮是一種潛在的1型糖尿病治療方法。CRO進行的體外實驗沒有得出確鑿的結果，但該公司計劃在今年晚些時候進行體內臨床前研究和IIa期研究。Biodexa的研發更新已包含在2024年2月向美國證券交易委員會提交的6-K表格中，新聞稿的發佈日期爲2024年2月23日。
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC宣佈了其用於治療瀰漫性中線神經膠質瘤（DMG）的 MTX110 I 期臨床試驗的業績良好。該試驗由哥倫比亞大學歐文醫學中心進行，顯示中位總存活率爲16.5個月，而同類隊列的中位總存活率爲10.0個月。儘管療效不佳，但結果還是不錯的，將在2024年7月的兒科神經腫瘤學國際研討會上發表。該研究還報告了一名患者的嚴重不良事件，被認爲與研究藥物無關。此外，Biodexa提供了託利米酮的最新情況，託利米酮是一種潛在的1型糖尿病治療方法。CRO進行的體外實驗沒有得出確鑿的結果，但該公司計劃在今年晚些時候進行體內臨床前研究和IIa期研究。Biodexa的研發更新已包含在2024年2月向美國證券交易委員會提交的6-K表格中，新聞稿的發佈日期爲2024年2月23日。
有用
沒用